An Emerging Trend of Methamphetamine Injection in Iran: A Critical Target for Research on Blood-Borne Infection Diseases

authors:

avatar Zahra Alam Mehrjerdi 1 , * , avatar Alireza Noroozi 2

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, IR Iran
Iranian National Center for Addiction Studies (INCAS), School of Advanced Medical Technologies (SAMT), Tehran University of Medical Sciences, Tehran, IR Iran
Hepatitis Monthly: Vol.13, issue 2; e8154
published online: February 28, 2013
article type: Editorial
received: September 12, 2012
revised: October 1, 2012
accepted: October 16, 2012
DOI: https://doi.org/10.5812/hepatmon.8154

how to cite: Alam Mehrjerdi Z, Noroozi A. An Emerging Trend of Methamphetamine Injection in Iran: A Critical Target for Research on Blood-Borne Infection Diseases. Hepat Mon. 2013;13(2):e8154. https://doi.org/10.5812/hepatmon.8154.

Recently, Iran has faced a rapidly growing HIV/AIDS problem particularly among injecting drug users (IDUs). A study on IDUs who had been admitted at some DICs in Iran revealed that 20.5% were infected with HIV and 43.4% were infected with HCV (1). Studies on drug injection in Iran have been generally oriented toward opioid users (2) and transmission of blood-borne infection diseases (3). In recent years, a new trend of methamphetamine injection is also observed in the community. Methamphetamine use could contribute to practicing injection, and transmission of blood-borne infection diseases. Studies in developed countries show that as a highly addictive psychostimulant drug, methamphetamine use can increase high-risk sexual behaviors and injection, and the risk of being infected with HIV, hepatitis, and tuberculosis (4-6). Compared to other substances, methamphetamine use is more often linked to increased casual partners and decreased condom use (7, 8), unprotected sex and increased risk for being infected with sexually transmitted infections (STIs) (9, 10), increased involvement in sex trade, needle sharing and failure to clean used needles (5, 11). A study on 139 heterosexual cases who were methamphetamine addicts showed that they reused syringes and shared needles (12). Risky sex among heterosexual and homosexual users of methamphetamine has also contributed to higher rates of hepatitis and HIV infection rates (13, 14). Methamphetamine use also interferes with the efficacy of HIV medications and treatment (15). Methamphetamine is a newly introduced drug in Iran. As a developing country, a recent UNODC world drug report shows that methamphetamine seizures are increasing in Iran (16). Currently, methamphetamine use is observed in emergency departments of psychiatric hospitals (17), among young people in the community (18), opiate-dependent patients who refer to methadone maintenance treatment (19), and IDUs who share syringes (20). In recent years, a harm reduction approach has been rapidly developed for IDUs in Iran. Methadone and buprenorphine maintenance treatment programs have become the main forms of harm reduction programs in the country since 2002 (21) and needle and syringe programs (NSPs) have contributed to a decrease in sharing practices among IDUs (22) but these programs have been implemented for injecting opiate users and it has remained unknown whether the current available interventions could meet the treatment needs of injecting methamphetamine users (IMUs) as a group of psychostimulant users in the country. It should be noted that Iranian IMUs are likely to be at risk for being infected with blood-borne infection diseases but the available information is often of poor quality. This issue may be partly due to the new presence of methamphetamine as a psychostimulant drug in the community. In the other words, in Iran, the investment in treatment of blood-borne infection diseases among IMUs is considerable in recent years. However, the investment in research has been inadequate, making it difficult to assess the epidemics of blood-borne infection diseases among IMUs and evaluate the efficacy of implemented treatment and harm reduction programs. It is possible that a high rate of blood-borne infection diseases has occurred among IMUs in some parts of Iran and has not been recognized yet. As a result, there is a need for conducting epidemiological studies on methamphetamine injection in Iran to investigate the prevalence of methamphetamine injection, the spread of blood-borne infection diseases and control its health implications in all parts of the country. Such studies could contribute to having a more complete nationwide profile of the problem, designing better prevention, treatment and harm reduction programs and improving the quality of current services based on the treatment needs and drug-related characteristics of IMUs. If such studies are not conducted, the healthcare system of Iran will have to prepare itself for long-term consequences of spreading blood-borne infection diseases that are associated with methamphetamine injection in the country. Future studies should be focused on breaking the cycle of blood-borne infection diseases by implementing multidisciplinary interventional approaches to control the spread of these infections among IMUs and to the general population. A study on the feasibility of offering late-night harm reduction services for a group of methamphetamine-using men showed that providing needle exchange, condoms, sexually transmitted infection testing and harm reduction education could decrease the risk of being infected with HIV (23). Drug use prevention and treatment programs that prevent or slow drug injection had profound effects on the HIV and HCV epidemics in other countries (24). Intervention efforts should be expanded progressively in Iran to include comprehensive prevention of blood-borne infection diseases with educational programs, and methamphetamine use therapy, and some therapeutic components such as specific drug-related educational programs must be incorporated for preventing blood-borne infection diseases among IMUs.

References

  • 1.

    Mirahmadizadeh AR, Majdzadeh R, Mohammad K, Forouzanfar MH. Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iran Red Crescent Med J. 2009;11(3):325-9.

  • 2.

    Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14(1):e28-33. [PubMed ID: 19464218]. https://doi.org/10.1016/j.ijid.2009.03.002.

  • 3.

    Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, et al. Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors. Int J Prev Med. 2012;3(Suppl 1):S131-8. [PubMed ID: 22826755].

  • 4.

    Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex. 2001;41(2):17-35. [PubMed ID: 11482426]. https://doi.org/10.1300/J082v41n02_02.

  • 5.

    Molitor F, Ruiz JD, Flynn N, Mikanda JN, Sun RK, Anderson R. Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. Am J Drug Alcohol Abuse. 1999;25(3):475-93. [PubMed ID: 10473010].

  • 6.

    Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102 Suppl 1:130-5. [PubMed ID: 17493062]. https://doi.org/10.1111/j.1360-0443.2006.01775.x.

  • 7.

    Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex Transm Dis. 2006;33(4):250-5. [PubMed ID: 16505748]. https://doi.org/10.1097/01.olq.0000194595.90487.ed.

  • 8.

    Semple SJ, Grant I, Patterson TL. Female methamphetamine users: social characteristics and sexual risk behavior. Women Health. 2004;40(3):35-50. [PubMed ID: 15829444].

  • 9.

    Carey JW, Mejia R, Bingham T, Ciesielski C, Gelaude D, Herbst JH, et al. Drug use, high-risk sex behaviors, and increased risk for recent HIV infection among men who have sex with men in Chicago and Los Angeles. AIDS Behav. 2009;13(6):1084-96. [PubMed ID: 18498049]. https://doi.org/10.1007/s10461-008-9403-3.

  • 10.

    Schwarcz S, Scheer S, McFarland W, Katz M, Valleroy L, Chen S, et al. Prevalence of HIV infection and predictors of high-transmission sexual risk behaviors among men who have sex with men. Am J Public Health. 2007;97(6):1067-75. [PubMed ID: 17463384]. https://doi.org/10.2105/AJPH.2005.072249.

  • 11.

    Lorvick J, Martinez A, Gee L, Kral AH. Sexual and injection risk among women who inject methamphetamine in San Francisco. J Urban Health. 2006;83(3):497-505. [PubMed ID: 16739050]. https://doi.org/10.1007/s11524-006-9039-4.

  • 12.

    Semple SJ, Patterson TL, Grant I. The context of sexual risk behavior among heterosexual methamphetamine users. Addict Behav. 2004;29(4):807-10. [PubMed ID: 15135564]. https://doi.org/10.1016/j.addbeh.2004.02.013.

  • 13.

    Greenwell L, Brecht ML. Self-reported health status among treated methamphetamine users. Am J Drug Alcohol Abuse. 2003;29(1):75-104. [PubMed ID: 12731682].

  • 14.

    Vogt TM, Perz JF, Van Houten CK, Jr, Harrington R, Hansuld T, Bialek SR, et al. An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment. Addiction. 2006;101(5):726-30. [PubMed ID: 16669906]. https://doi.org/10.1111/j.1360-0443.2006.01407.x.

  • 15.

    Boddiger D. Metamphetamine use linked to rising HIV transmission. Lancet. 2005;365(9466):1217-8. [PubMed ID: 15816071]. https://doi.org/10.1016/S0140-6736(05)74794-2.

  • 16.

    ed. Vienna, Austria; 2012. World drug report. Available from: http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf.

  • 17.

    Zarghami M. Methamphetamine has changed the profile of patients utilizing psychiatric emergency services in Iran. Iran J Psychiatr Behav Sci. 2011;5(1):1-5.

  • 18.

    Momtazi S, Rawson R. Substance abuse among Iranian high school students. Curr Opin Psychiatry. 2010;23(3):221-6. [PubMed ID: 20308905]. https://doi.org/10.1097/YCO.0b013e328338630d.

  • 19.

    Mokhber N, Afshari R, Farhoodi F. Evaluation of the suicide risk factors among methadone maintenance treatment of opiate dependent individuals: A six month assessment. Open J Psychiatry. 2012;2(2):91-5.

  • 20.

    Rafiey H, Narenjiha H, Shirinbayan P, Noori R, Javadipour M, Roshanpajouh M, et al. Needle and syringe sharing among Iranian drug injectors. Harm Reduct J. 2009;6:21. [PubMed ID: 19643014]. https://doi.org/10.1186/1477-7517-6-21.

  • 21.

    Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, Power R. HIV/AIDS harm reduction in Iran. Lancet. 2006;368(9534):434-5. [PubMed ID: 16890814]. https://doi.org/10.1016/S0140-6736(06)69132-0.

  • 22.

    Vazirian M, Nassirimanesh B, Zamani S, Ono-Kihara M, Kihara M, Ravari SM, et al. Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J. 2005;2:19. [PubMed ID: 16212655]. https://doi.org/10.1186/1477-7517-2-19.

  • 23.

    Rose VJ, Raymond HF, Kellogg TA, McFarland W. Assessing the feasibility of harm reduction services for MSM: the late night breakfast buffet study. Harm Reduct J. 2006;3:29. [PubMed ID: 17018154]. https://doi.org/10.1186/1477-7517-3-29.

  • 24.

    Vlahov D, Fuller CM, Ompad DC, Galea S, Des Jarlais DC. Updating the infection risk reduction hierarchy: preventing transition into injection. J Urban Health. 2004;81(1):14-9. [PubMed ID: 15047779]. https://doi.org/10.1093/jurban/jth083.